Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

被引:130
作者
Sholl, Lynette M. [1 ]
Weremowicz, Stanislawa [1 ]
Gray, Stacy W. [2 ]
Wong, Kwok-Kin [2 ]
Chirieac, Lucian R. [1 ]
Lindeman, Neal I. [1 ]
Hornick, Jason L. [1 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Thorac Oncol, Boston, MA 02115 USA
关键词
Anaplastic lymphoma kinase; Lung adenocarcinoma; Fluorescence in situ hybridization; Immunohistochemistry; CANCER; FUSION; MUTATIONS; GEFITINIB; EGFR;
D O I
10.1097/JTO.0b013e31827db604
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: ALK gene rearrangements occur in approximately 5% of lung adenocarcinomas (ACAs), leading to anaplastic lymphoma kinase (ALK) overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the standard procedure for detection of ALK rearrangements in lung ACA but requires specialized equipment and expertise. Immunohistochemistry (IHC) for ALK protein overexpression is a promising screening modality, with reports of newer antibodies showing excellent sensitivity and specificity for ALK-rearranged lung ACA. Methods: In this study, we analyzed ALK IHC (5A4 clone) in 186 cases from our clinical service and compared it with ALK FISH and EGFR and KRAS mutation status. Results: Twelve cases had concordant ALK protein overexpression and ALK rearrangement by FISH. Three ALK-rearranged cases lacked ALK protein expression. Of these discrepant cases, one had a coexisting EGFR mutation and a subtle atypical ALK rearrangement manifested as a break in the 5' centromeric portion of the FISH probe. One case had a concurrent BRAF mutation. Follow-up testing on a metastasis revealed absence of the ALK rearrangement, with persistent BRAF mutation. In one ALK-rearranged protein negative case, very limited tissue remained for ALK IHC, raising the possibility of false negativity because of protein expression heterogeneity. Importantly, ALK protein expression was detected in one case initially thought not to have an ALK rearrangement. In this case, FISH was falsely negative because of interference by benign reactive nuclei. After correcting for these cases, ALK IHC was 93% sensitive and 100% specific as compared with FISH. Conclusions: ALK IHC improves the detection of ALK rearrangements when used together with FISH, and its use in lung ACA genetic testing algorithms should be considered.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [21] Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
    Voena, Claudia
    Menotti, Matteo
    Mastini, Cristina
    Di Giacomo, Filomena
    Longo, Dario Livio
    Castella, Barbara
    Merlo, Maria Elena Boggio
    Ambrogio, Chiara
    Wang, Qi
    Minero, Valerio Giacomo
    Poggio, Teresa
    Martinengo, Cinzia
    D'Amico, Lucia
    Panizza, Elena
    Mologni, Luca
    Cavallo, Federica
    Altruda, Fiorella
    Butaney, Mohit
    Capelletti, Marzia
    Inghirami, Giorgio
    Jaenne, Pasi A.
    Chiarle, Roberto
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (12) : 1333 - 1343
  • [22] Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases
    Ambrosini, Paolo
    Miliziano, Daniela
    Di Liberti, Giorgia
    Lorenzini, Daniele
    Marchesi, Silvia
    Bassetti, Anna
    Tamborini, Elena
    Leporati, Rita
    Beninato, Teresa
    Mazzeo, Laura
    Brambilla, Marta
    Ganzinelli, Monica
    Prelaj, Arsela
    Proto, Claudia
    De Braud, Filippo Guglielmo
    Lo Russo, Giuseppe
    Occhipinti, Mario
    CLINICAL LUNG CANCER, 2025, 26 (01) : e11 - e17
  • [23] ALK-rearranged renal cell carcinomas in Polish population
    Gorczynski, Adam
    Czapiewski, Piotr
    Korwat, Aleksandra
    Budynko, Lukasz
    Prelowska, Monika
    Okon, Krzysztof
    Biernat, Wojciech
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [24] Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
    Takeyasu, Yuki
    Okuma, Hitomi S.
    Kojima, Yuki
    Nishikawa, Tadaaki
    Tanioka, Maki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Arakawa, Ayumu
    Mori, Taisuke
    Sunami, Kuniko
    Kubo, Takashi
    Kohno, Takashi
    Akihiko, Yoshida
    Yamamoto, Noboru
    Yonemori, Kan
    JCO PRECISION ONCOLOGY, 2021, 5 : 756 - 766
  • [25] Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Co-Altered Lung Adenocarcinoma
    Cai, Weijing
    Zhou, Caicun
    Lin, Dongmei
    Wu, Chunyan
    Li, Xuefei
    Zhao, Chao
    Zheng, Limou
    Fei, Ke
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S297 - S297
  • [26] ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
    Mota, Ines
    Patrucco, Enrico
    Mastini, Cristina
    Mahadevan, Navin R.
    Thai, Tran C.
    Bergaggio, Elisa
    Cheong, Taek-Chin
    Leonardi, Giulia
    Karaca-Atabay, Elif
    Campisi, Marco
    Poggio, Teresa
    Menotti, Matteo
    Ambrogio, Chiara
    Longo, Dario L.
    Klaeger, Susan
    Keshishian, Hasmik
    Sztupinszki, Zsofia M.
    Szallasi, Zoltan
    Keskin, Derin B.
    Duke-Cohan, Jonathan S.
    Reinhold, Bruce
    Carr, Steven A.
    Wu, Catherine J.
    Moynihan, Kelly D.
    Irvine, Darrell J.
    Barbie, David A.
    Reinherz, Ellis L.
    Voena, Claudia
    Awad, Mark M.
    Blasco, Rafael B.
    Chiarle, Roberto
    NATURE CANCER, 2023, 4 (07) : 1016 - +
  • [27] A Case of a Pregnant Woman Diagnosed as Having ALK-rearranged Lung Adenocarcinoma
    Komura, Moegi
    Yagishita, Shigehiro
    Nakamura, Kota
    Arano, Naoko
    Takeshige, Tomohito
    Muraki, Keiko
    Nagashima, Osamu
    Izumi, Hiroshi
    Tomita, Shigeki
    Sasaki, Shinichi
    Takahashi, Kazuhisa
    IN VIVO, 2018, 32 (05): : 1205 - 1209
  • [28] Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting
    Testa, Ugo
    Castelli, Germana
    Pelosi, Elvira
    TUMORI JOURNAL, 2024, 110 (02): : 88 - 95
  • [29] Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
    Jamme, Philippe
    Descarpentries, Clotilde
    Gervais, Radj
    Dansin, Eric
    Wislez, Marie
    Gregoire, Valerie
    Richard, Nicolas
    Baldacci, Simon
    Rabbe, Nathalie
    Kyheng, Maeva
    Kherrouche, Zoulika
    Escande, Fabienne
    Copin, Marie Christine
    Cortot, Alexis B.
    CLINICAL LUNG CANCER, 2019, 20 (04) : 297 - +
  • [30] A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry
    Gruber, Kim
    Kohlhaeufl, Martin
    Friedel, Godehard
    Ott, German
    Kalla, Claudia
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 713 - 716